Results 21 to 30 of about 765,112 (149)

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. [PDF]

open access: yes, 2017
Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown.
Gavrilovic, Igor T.   +101 more
core   +2 more sources

The protein tyrosine kinases EpsB and PtkA differentially affect biofilm formation in Bacillus subtilis [PDF]

open access: yes, 2014
The Gram-positive soil bacterium Bacillus subtilis is able to choose between motile and sessile lifestyles. The sessile way of life, also referred to as biofilm, depends on the formation of an extracellular polysaccharide matrix and some extracellular ...
Stanley-Wall, Nicola   +6 more
core   +1 more source

Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus

open access: yesFrontiers in Medicine, 2021
Bruton Tyrosine Kinase (BTK) has a key role in multiple pathways involved in inflammation and autoimmunity. Therefore, BTK has become a new therapeutic target for a group of hematologic and autoimmune disorders.
Aikaterini Patsatsi, Dedee F. Murrell
doaj   +1 more source

Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study assessed whether upper cervical cord area (UCCA) measured on routine brain MRI can serve as a biomarker of conversion to SPMS. Methods This is a single‐center retrospective cohort study of RRMS patients with cross‐sectional and longitudinal analyses of clinical and MRI data. Future SPMS converters were matched by age, sex,
Nabil K. El Ayoubi   +8 more
wiley   +1 more source

Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2 [PDF]

open access: yes, 2002
Receptor tyrosine kinases (RTKs) play distinct roles in multiple biological systems. Many RTKs transmit similar signals, raising questions about how specificity is achieved.
Zhang, S.   +13 more
core   +1 more source

The impact of pausing Bruton Tyrosine Kinase inhibitor (BTKi) therapy versus continued therapy on vaccination immune response in patients with chronic lymphocytic leukaemia: the IMPROVE RCT

open access: yesEfficacy and Mechanism Evaluation
Background Chronic lymphocytic leukaemia is the most common leukaemia subtype and associated with profound immunosuppression. Bruton Tyrosine Kinase inhibitors have revolutionised chronic lymphocytic leukaemia management; however, Bruton Tyrosine Kinase ...
Jonathan A Cook   +16 more
doaj   +1 more source

Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny [PDF]

open access: yes
Bruton tyrosine kinase (Btk) has long been known to play a key role in chronic lymphatic leukaemia, Waldenström macroglobulinaemia and other B-cell proliferative disorders.
Camilli, Massimiliano   +1 more
core   +1 more source

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL

open access: yesNature Communications, 2020
Ibrutinib, a Bruton tyrosine kinase inhibitor, provides effective treatment for chronic lymphocytic leukemia (CLL). Here, the authors describe time-dependent molecular changes to malignant cells and to the immune system in patients undergoing ibrutinib ...
André F. Rendeiro   +14 more
doaj   +1 more source

Baseline Neuroinflammation Stratifies TSPO‐PET Response to Disease‐Modifying Therapy in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate which baseline clinical and imaging characteristics best predict TSPO‐PET‐measurable reduction in glial activation following treatment of multiple sclerosis (MS), to utilize this information for designing more efficient biomarker‐based clinical trials targeting glial activation.
Marlene T. Morch   +5 more
wiley   +1 more source

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?

open access: yesImmunoTargets and Therapy, 2020
Ana Lorenzo-Vizcaya,1 Serena Fasano,2 David A Isenberg3 1Department of Internal Medicine, Hospital Universitario De Ourense, Ourense, Spain; 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Campania L.
Lorenzo-Vizcaya A, Fasano S, Isenberg DA
doaj  

Home - About - Disclaimer - Privacy